JCR Pharmaceuticals Co., Ltd. (TYO:4552)
Japan flag Japan · Delayed Price · Currency is JPY
499.00
+6.00 (1.22%)
Nov 13, 2026, 3:25 PM JST

JCR Pharmaceuticals Cash Flow Statement

Millions JPY. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
-3,4353,224-5,9837,2445,41219,404
Depreciation & Amortization
2,1792,5573,3743,1971,9971,945
Loss (Gain) From Sale of Investments
-412-667----
Loss (Gain) on Equity Investments
1841844671,090--
Other Operating Activities
-1,662750-2,2771,982-8,280-2,520
Change in Accounts Receivable
-1,396-1,9272,698-3,7974,448-7,402
Change in Inventory
-1,090-1,853-1,253-2,437-3,877-1,082
Change in Accounts Payable
40290-2,3071,854-2,8921,305
Change in Other Net Operating Assets
-656-2,693-510179-2,308-2,361
Operating Cash Flow
-6,155-135-5,7919,312-5,5009,289
Operating Cash Flow Growth
------10.17%

Investing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-18,434-11,427-9,582-1,526-7,654-11,333
Cash Acquisitions
-350---600-6,717-
Divestitures
--145---
Sale (Purchase) of Intangibles
-154-154--569-906-
Investment in Securities
1,3941,670--259-
Other Investing Activities
-2,640-2,593-1325168,083
Investing Cash Flow
-20,184-12,504-9,569-2,690-15,002-3,250

Financing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
-15,08714,805-3,000-
Long-Term Debt Issued
-3,7507509,6004,750750
Total Debt Issued
25,35118,83715,5559,6007,750750
Short-Term Debt Repaid
----6,900--
Long-Term Debt Repaid
--3,050-750-2,200-3,050-750
Total Debt Repaid
-1,800-3,050-750-9,100-3,050-750
Net Debt Issued (Repaid)
23,55115,78714,8055004,700-
Issuance of Common Stock
5821---
Repurchase of Common Stock
---2,530151010
Common Dividends Paid
-2,441-2,441-2,505-2,500-2,739-2,169
Other Financing Activities
-44-49-55-46-23-20
Financing Cash Flow
21,07113,3059,736-2,0311,948-2,179

Net Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
82145648861,099612
Miscellaneous Cash Flow Adjustments
--1-1-
Net Cash Flow
-5,186811-5,5595,477-17,4544,472

Free Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
-24,589-11,562-15,3737,786-13,154-2,044
Free Cash Flow Growth
------
Free Cash Flow Margin
-63.16%-28.68%-46.48%18.16%-38.30%-4.00%
Free Cash Flow Per Share
-201.47-94.76-124.1562.09-105.37-16.46
Levered Free Cash Flow
-35,002-23,966-13,3344,178-15,2354,843
Unlevered Free Cash Flow
-34,640-23,718-13,2374,232-15,2074,871

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
606413147874645
Cash Income Tax Paid
262-7632,284-1,9828,2792,517
Change in Working Capital
-3,102-6,183-1,372-4,201-4,629-9,540